Evotec's Partnerships Keep Coming, but the Market Is Reading a Different Script
Published on 09/10/2026 at 22:40 | Editorial boerse-global.de
Evotec shares touched a fresh 52-week low of EUR 3.00, drifting 2.8% lower on the day without any single piece of news to blame. That absence of a trigger is itself the story: investors no longer need a reason to sell. What has gone missing is structural confidence.
The stock now sits just above its prior 52-week floor of EUR 3.12, having surrendered more than half its value since peaking at EUR 7.75 last November. Tuesday's decline extends a slump that has run through every time frame — down 44% year-to-date and 48% over twelve months, 37% below the 200-day moving average and 15% under the 50-day line. The relative strength index has slipped to 30.7, a reading that flags oversold conditions but offers little comfort to anyone watching how far the liquidation has already run.
A Guidance Cut That Still Sets the Tone
The real weight on the shares traces back to mid-July, when Evotec slashed its 2026 outlook: revenue guidance was cut from EUR 700–780 million to EUR 570–610 million, while the projected adjusted EBITDA loss widened from a range of 0 to 40 million euros to 70–105 million euros. August's half-year report confirmed the reduced targets rather than softening them. First-half revenue fell 19.2% to EUR 300.1 million, and adjusted EBITDA came in at minus EUR 42.7 million. Nearly two months on, that guidance cut remains the anchor for how the market values the Tübingen-based drug developer.
Against that backdrop, the steady drip of partnership news has done little to shift sentiment. Roughly a week ago, Evotec announced a collaboration with Plectonic Biotech, pairing its in-house BiTCo platform with the partner's LOGIBODY technology to pursue T-cell-engaging approaches against solid tumors. The stock has lost 6.4% since. An earlier AI-driven research alliance with Odyssey Therapeutics, unveiled more than a month ago in the autoimmune and inflammatory disease space, failed to halt the slide as well — shares are down 10.8% since that announcement.
Should investors sell immediately? Or is it worth buying Evotec?
That pattern is telling. Evotec is delivering operational substance: fresh research collaborations, a broad platform technology, ties to well-known partners. Yet the market is pricing the hard numbers of the current business rather than the potential of new deals — and those numbers are sobering.
Horizon Holds the Key
The decisive variable for the months ahead is whether the "Horizon" transformation, announced in March, actually delivers the promised cost savings. Management intends to shrink the global site footprint to ten locations and save roughly EUR 75 million by the end of 2027, with 20% to 30% of that total already booked this year. Restructuring costs of EUR 75 million were incurred in the first quarter alone. For shareholders, the question that matters is not the next collaboration headline but whether those savings show up in upcoming quarterly results and stabilize free cash flow.
There is a bull case here. If Evotec hits its savings targets, adjusted EBITDA could steady faster than the market currently assumes. The Plectonic tie-up and the earlier Odyssey deal at least demonstrate that the company's research engine — including the BiTco technology for bispecific antibodies — continues to draw partner interest. Milestone payments from such arrangements could add liquidity without Evotec committing its own capital. And with Claire Hinshelwood installed as finance chief since May, the company has fresh leadership in the finance function to see the restructuring through.
The bear case rests on the combination of shrinking revenue and persistent restructuring charges. A nearly one-fifth decline in first-half sales shows the core business is under pressure, and collaboration announcements alone do not offset that — the share price reaction of recent weeks makes the point. The departure of Camilla Macapili Languille from the supervisory board roughly a month ago, relinquishing her independent mandate and her seat on the Audit & Compliance Committee, has further fed doubts about management continuity at a critical juncture; the stock has shed 11.5% since. Board turnover happens without necessarily saying anything about operations, but in a climate where every headline is read negatively, it adds up.
What Comes Next
Should Horizon deliver its savings on schedule and the partnership pipeline keep attracting new partners, there is room for the shares to find a floor near current levels. If revenue keeps eroding or the Horizon effects slip, the already-reduced guidance could come under question again — with the corresponding downward pressure. The next concrete test arrives with third-quarter figures, which will show whether the cost measures are actually reaching the bottom line. Until then, Evotec remains a case of operational progress pitted against structural doubt, and the market is keeping score on only one side of that ledger.
Ad
Evotec Stock: New Analysis - 10 September
Fresh Evotec information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
